Breckenridge to market Gabapentin capsules
As part of the agreement, Marksans will manufacture and supply the product to Breckenridge, who will hold US marketing and distribution rights. Gabapentin, which was approved by the
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).